Pre-exposure Prophylaxis (PrEP)
|
|
- Cecily Baker
- 5 years ago
- Views:
Transcription
1 Pre-exposure Prophylaxis (PrEP) Kenneth Mayer, MD Fenway Health Beth Israel Deaconess Medical Center Harvard Medical School and School of Public Health Treatment As Prevention in Africa Workshop May 2 nd, 2014
2 Why Chemoprophylaxis Post-HPTN 052? TasP long term effectiveness not fully understood HIV incidence has not in several resource rich countries despite access (Birrell, 2013; Audelin, 2013) U.S. Cascade < 30% PLHIV virologically suppressed Serostatus awareness is limited among many Not all PLHIV want to start meds with high CD4 counts, and virologic suppression rates vary HIV stigma limits willingness to disclose Cost effectiveness of PrEP : 44 PubMed cites Not either/or, especially if PreP is limited to the riskiest people, e.g. women in South Africa (Walensky, et al, CID, 2012)
3 PrEP works, but adherence is critical Study Efficacy overall Drug detected overall Estimated Risk reduction with drug iprex 42% ~50% 92% Partners PrEP 67-75% 82% 86% (TDF) 90% (FTC/TDF) TDF-2 62% 80% 78% Fem-PrEP No efficacy 26% adherence too low to assess efficacy VOICE No efficacy 29% Thai IDU 49% N/A N/A
4 Residual PrEP Concerns Risk Compensation: not seen in trials Renal insufficiency: rare, reversible -but pts had to have normal function for trials Bone demineralization: statistically significant, not clinically significant at 18 months, needs f/u Transmission of resistance -Primarily in pts started on PrEP with acute HIV -Most were 184V (3TC/FTC R, less fit virus) Role of Genital Tract Inflammation and PK need f/u (Naranbhai, JID, 2012; Hendrix, CROI, 2014)
5 Buchbinder et al, Lancet ID, 2014
6 Strategies to improve PrEP delivery and adherence New PrEP drugs and dosing strategies Novel adherence strategies Alternative delivery systems and formulations Topical Microbicides: TFV vaginal or rectal gel Intra-vaginal rings: ASPIRE (Dapivirine) Injectables: Rilpivirine-LA GSK744
7 TFV- DP Concentra0ons in IPrEx and STRAND TFV-DP (fmol/10 6 Cells) STRAND 16 iprex Regression analysis in iprex: 90% reduction in HIV acquisition when TFV-DP>16 fmol/10 6 cells Predicted risk reduction: 76% with 2 pills / week 96% with 4 pills / week 99% with 7 pills/ week 1 2/Wk 4/Wk 7/Wk n = 21 n = 21 n = 22 BLQ: 0% 0% 0% Median: IQR: Cases Controls n = 42 n = % 64% * nt * Visit when HIV was first discovered Anderson et al, Science Translational Medicine :151ra125
8 Tenofovir PBMC v. Plasma (HPTN 066) (Hendrix C et al, CROI, 2014) PBMC Tenofovir diphosphate Plasma Tenofovir TFV-DP fmol/m cells PBMC Weekly 1x Twice weekly 2x Twice Weekly Daily TFV ng/ml Plasma Weekly 1x Twice weekly 2x Twice Weekly Daily Days Days
9 HPTN 067/ADAPT (Alterna0ve dosing to augment PrEP pill taking) Phase II, Randomized, Open-Label, Pharmacokinetic and Behavioral Study of the Use of Intermittent Oral PrEP with TDF/FTC Wk 24 primary endpoint 6-week lead-in period 1 pill/week DOT before randomization Daily Truvada 1 tablet/d Regarless of sexual activity (n = 180) High risk women and MSM (New York, Bangkok, Cape Town) Time driven Truvada: 1 tablet 2 days/week + 1 post-exposure dose within 2 hours after sex (n = 180) Event driven Truvada: 1 tablet prior to sex + 1 post-exposure dose within 2 hours after sex (n = 180) Primary Objective: Is intermittent vs. daily dosing associated with equivalent coverage of sex events, lower number of pills used and decreased side effects R. Grant, F. Van Griensven, et al.
10 US PrEP Demonstra0on Project: Implementa0on of PrEP ( ) STD clinics in San Francisco, Miami, Washington, DC (n=831) - MSM, transgender women (1.4%) - Clinic referrals (63%) - Self- referrals (37%): more likely to be white, higher educa0on level, higher sexual risk behaviors and risk percep0on versus clinic referrals Offered up to 48 weeks of open- label emtricitabine/tenofovir DF - Accepted PrEP: 60.4% 77% had TDF- DP levels consistent with taking >4 doses/week PrEP uptake associated with - Self- referral, prior PrEP awareness, higher- risk sexual behaviors BLD: below limit of detecfon. Cohen SE, et al. 21 st CROI. Boston, Abstract 954. Samples (%) Tenofovir- DP Levels (Week 4) Miami (n=157) Washington, DC (n=100) San Francisco (n=300) 27% 18% 43% 43% 40% 10 11% 0 5% 4% 4% 2% 2% 0% BLD < > Doses/Week: <2 <2 2 4 >4 Tenofovir- DP (fmol/punch)* *femtomole/punch: measure of flux density. 14% 35% >950 52%
11
12 PrEP Proof-of-Concept: Long-Acting Integrase Inhibitor in Nanosuspension for Injection Macaque model of SHIV transmission Study 1 (vaginal transmission) - Low-dose SHIV (50 TCID 50 ) twice a week - GSK744 LA (50 mg/kg) 3 injections at week 0, 4, 8-6 of 6 pigtail macaques (lunar menstrual cycles) protected against SHIV infection Study 2 (rectal transmission) - Weekly SHIV (50 TCID 50 ) until systemic infection detected - One GSK744 LA (50 mg/kg) injection at week 0 - After 1 to 2 challenges, placebo macaques became infected - With a single GSK744 injection, infection was delayed by 5 to 10 challenges with SHIV Radzlo J, et al. 21 st CROI. Boston, Abstract 40LB. Andrews CD, et al. 21 st CROI. Boston, Abstract 39. Andrews CD, et al. Science. 2014;343: Aviremic (%) Aviremic (%) Vaginal SHIV Exposure P= GSK744 LA (n=6) Placebo (n=6) Week Rectal SHIV Exposure P< GSK744 LA (n=12) Placebo (n=4) Week
13 Project PrEPare (NIMH R34,Fenway) Modeled after Life-Steps, (Safren et al) ART adherence intervention Modular intervention: 4 weekly visits and 2 booster sessions (nurse-delivered). Intervention content: CBT-oriented adherence problem-solving Brief motivational interviewing Identification of barriers and solutions Sexual risk-reduction strategies Optional modules: Mental health and substance use concerns 13 Adherence to PrEP was measured daily via Wisepill Sexual risk taking was assessed by text messages (Lester, 2010)
14 To implement PrEP successfully, it will be essenfal to engage pracfcing clinicians Fenwayfocus.org
15 Candidates for PrEP studies in Africa HIV discordant couples: HIV+ partner does not want to start ART Bridge for newly initiating HIV+ (Partners PrEP Demo) PrEP-ception MSM HPTN 075: MSM in Kenya, Malawi, South Africa MSM with wives: how can they explain condoms? FSW: which ones? High risk heterosexuals? Botswana: yes; VOICE, FEMPrEP: questions.
16 Combination Antiretroviral Prevention Interventions to Increase Testing HIV Negative Risk Assessment PrEP, Adherence Counseling Test HIV Positive Positive Prevention Linkage To Care Address concomitant concerns, e.g. depression, substance use, relationship dynamics Enroll in Care Treat ART Initiation Adherence to ART Maintain Viral Suppression. Decrease in HIV Transmission
17 Thank You Fenway Clinical, Epidemiological and Behavioral Research Teams Fenway Medical Department Slim and Quarraisha Abdool Karim Susan Buchbinder Connie Celum Robert Grant Doug Krakower Albert Liu Jim Rooney Steve Safren Dawn Smith NIAID, NIMH, NIDA, NICHD, CDC, HRSA, Mass DPH, Gilead
Microbicides and Antiretroviral Therapy
Microbicides and Antiretroviral Therapy Kenneth H. Mayer, M.D. Fenway Health/Beth Israel Deaconess Hospital/Harvard Medical School Infected Genital Leukocytes and Cell-Associated Virus Transmission October
More informationPrEP: State of the ART
PrEP: State of the ART Kenneth H. Mayer, M.D. Fenway Health Beth Israel Deaconess Medical Center Harvard Medical School & School of Public Health Disclosure: Unrestricted research/educational grants from
More informationBiomedical Interventions for HIV Prevention
Biomedical Interventions for HIV Prevention Kenneth H. Mayer Fenway Health/Beth Israel Deaconess Medical Center Harvard Medical School and School of Public Health September 27 th, 2013 HIV Prevention Interventions
More informationPre-exposure prophylaxis : Systemic and topical. Linda-Gail Bekker The Desmond Tutu HIV Centre UCT SA HIV ClniciansSociety Conference 2012
New biomedical technologies. Pre-exposure prophylaxis : Systemic and topical. Linda-Gail Bekker The Desmond Tutu HIV Centre UCT SA HIV ClniciansSociety Conference 2012 And the last parachute goes to..
More informationAntiretroviral Drugs for HIV Seronegative People: It works in trials, what about the real world?
Antiretroviral Drugs for HIV Seronegative People: It works in trials, what about the real world? Lut Van Damme 11 Oct 2012 1 Disclaimer Gilead donated the study product for the FEM-PrEP trial I participated
More informationRoy M. Gulick, MD, MPH Chief, Division of Infectious Diseases Professor of Medicine Weill Medical College of Cornell University New York City
PrEP 2013 Roy M. Gulick, MD, MPH Chief, Division of Infectious Diseases Professor of Medicine Weill Medical College of Cornell University New York City Slide #2 U.S.: New HIV Infections Per Year ~50,000
More informationHIV Prevention: 2010
Antiretrovirals for Prevention: Opportunities and Challenges for TREAT Asia KENNETH H. MAYER, M.D. BROWN UNIVERSITY/MIRIAM HOSPITAL FENWAY HEALTH HIV Prevention: 2010 DECREASE SOURCE OF INFECTION Barrier
More informationBiomedical Prevention Update Thomas C. Quinn, M.D.
Biomedical Prevention Update Thomas C. Quinn, M.D. Associate Director of International Research National Institute of Allergy and Infectious Diseases Director, Johns Hopkins Center for Global Health Global
More informationCombination HIV Prevention Research Carl W. Dieffenbach, Ph.D.
Combination HIV Prevention Research Carl W. Dieffenbach, Ph.D. Director, Division of AIDS, NIAID, NIH October 13, 2011 Multiple strategies needed to assemble a wellrounded prevention toolkit Know the epidemics
More informationHIV Prevention Strategies HIV Pre-exposure prophylaxis
HIV Prevention Strategies HIV Pre-exposure prophylaxis Michael Martin, MD, MPH Director HIV Research Program Thailand MOPH U.S. CDC Collaboration The findings and conclusions in this presentation are those
More informationART and Prevention: What do we know?
ART and Prevention: What do we know? Biomedical Issues Trip Gulick, MD, MPH Chief, Division of Infectious Diseases Professor of Medicine Weill Cornell Medical College New York City ART for Prevention:
More informationDrug development in relation to PrEP and the PROUD study
Drug development in relation to PrEP and the PROUD study David Dolling Medical Statistician MRC Clinical Trials Unit 18 th October 2012 What is PrEP? - Pre-exposure Prophylaxis A strategy that uses antiretrovirals
More informationSupplementary Material Table 5. Ongoing PrEP studies among young key population, young people, and key populations. Age range. Study name and location
Supplementary Material Table 5. Ongoing PrEP studies among young key population, young people, and key populations Study name and location ADAPT (HPTN 067) South Africa, Thailand, US (Harlem) Bangkok Tenofovir
More informationPrEP and Behavioral Strategies for HIV Prevention. Douglas Krakower, MD January 30, 2014
PrEP and Behavioral Strategies for HIV Prevention Douglas Krakower, MD January 30, 2014 Potential Competing Interests Dr. Krakower: investigator-initiated research regarding HIV prevention National Institutes
More informationThe Science behind Preexposure Prophylaxis (PrEP) Yunus Moosa Department of Infectious Diseases UKZN
The Science behind Preexposure Prophylaxis (PrEP) Yunus Moosa Department of Infectious Diseases UKZN 1 Ongoing HIV transmission despite expanding access to ART SA 18 16 14 12 10 8 6 4 2 0 Treatment exposure
More informationThe HIV Prevention Pill: The State of PrEP Science and Implementation. James Wilton Coordinator, Biomedical Science of HIV Prevention CATIE
The HIV Prevention Pill: The State of PrEP Science and Implementation James Wilton Coordinator, Biomedical Science of HIV Prevention CATIE Overview 1. The Basics 2. A review of the science 3. An update
More informationReview of planned trials and key emerging issues for Thailand
Review of planned trials and key emerging issues for Thailand Frits van Griensven, PhD, MPH Silom Community Clinic Thailand MOPH US CDC Collaboration US Centers for Disease Control and Prevention ilom
More informationOverview of ARV-based prevention trials
Overview of ARV-based prevention trials Catherine Hankins BA MD MSc CCFP FRCPC Deputy Director, Science Amsterdam Institute for Global Health and Development; Department of Global Health, Academic Medical
More informationUpdate on PrEP progress: WHO/UNAIDS challenges and actions
Update on PrEP progress: WHO/UNAIDS challenges and actions Kevin R. O'Reilly Prevention in the Health Sector, HIV/AIDS Department, WHO HQ Outline Review current status of PrEP Planning for PrEP Pre-exposure
More informationPharmacology Considerations for HIV Prevention
Pharmacology Considerations for HIV Prevention Peter L. Anderson University of Colorado Anschutz Medical Campus Skaggs School of Pharmacy and Pharmaceutical Sciences Perspectives for next generation studies
More information10/05/2016. PrEP : from proof of concept to real life. E. CUA Nice university hospital
PrEP : from proof of concept to real life E. CUA Nice university hospital 1 Disclosures Received honoraria and acted as consultant : Merck, Gilead, ViiV Co-investigator: Merck, Gilead, ViiV and BMS phase
More informationWhere are we going after effectiveness studies?
Where are we going after effectiveness studies? Nyaradzo M. Mgodi (MBChB, MMed) UZ-UCSF Collaborative Research Program Harare, Zimbabwe MTN Annual Meeting 28 March 2011, Arlington, VA Introduction 30 years
More informationPrEP Dosing Strategies
PrEP Dosing Strategies Outline o Background PrEP absorption and tissue penetration o Oral versus topical o Lead in and lead out dosing Time to protection o Cycling on and off PrEP o Balancing toxicity
More informationAntiretroviral Pharmacology for PrEP: Enhancing RCT Understanding with Small Intensive Studies
Antiretroviral Pharmacology for PrEP: Enhancing RCT Understanding with Small Intensive Studies Craig W. Hendrix, MD Director, Drug Development Unit Division of Clinical Pharmacology Johns Hopkins University
More informationCombination prevention: Public health and human rights imperatives
Combination prevention: Public health and human rights imperatives Gottfried Hirnschall, MD MPH HIV/AIDS Department WHO, Geneva London, June 11, 2012 Outline The epidemic and response What is combination
More informationUnderstanding the Results of VOICE
CONTACT: Lisa Rossi +1-412- 916-3315 (mobile) or +27-(0)73-323-0087 (through 7 March) rossil@upmc.edu About VOICE Understanding the Results of VOICE VOICE Vaginal and Oral Interventions to Control the
More informationART for HIV Prevention:
ART for HIV Prevention: KENNETH H. MAYER, M.D. Brown University/The Fenway Institute August 22, 2009 APPROACHES TO PREVENT HIV TRANSMISSION DECREASE SOURCE OF INFECTION Barrier Protection Treat STI Antiretroviral
More informationPsychosocial Issues in ART and HIV Prevention. Steven A. Safren, PhD
Psychosocial Issues in ART and HIV Prevention Steven A. Safren, PhD MSM, Mental Health, and Sexual Health 1. Why is behavioral science important when using ART as prevention? 2. How can we address the
More informationUpdate on ARV based PrEP
Update on ARV based PrEP Z Mike Chirenje MD FRCOG University of Zimbabwe, College of Health Sciences, Dept. of Obstetrics and Gynaecology Avondale, Harare, Zimbabwe chirenje@uz-ucsf.co.zw Controlling HIV
More informationUsing anti-hiv drugs for prevention
Using anti-hiv drugs for prevention Highlights from AIDS 2012 (and 2 nd International Workshops on Treatment as Prevention) Tim Rogers, trogers@catie.ca Using anti-hiv Drugs for Prevention Outline Treatment
More informationART and Transmission. Martin Fisher. Brighton and Sussex University Hospitals, UK
ART and Transmission Martin Fisher Brighton and Sussex University Hospitals, UK 11th Advanced HIV Course Aix-en-Provence 2013 New HIV diagnoses by exposure group: United Kingdom, 2002 2011 1 Predicted
More informationThe HIV Prevention Pill: The State of PrEP Science and Implementation
The HIV Prevention Pill: The State of PrEP Science and Implementation James Wilton Coordinator, Biomedical Science of HIV Prevention CATIE December 11 th, 2014 Overview 1. The Basics 2. A review of the
More informationThe Role of TAF in PrEP. Dr. Garrett has nothing to disclose
The Role of TAF in PrEP KATY GARRETT, PHARMD UNIVERSITY OF NORTH CAROLINA Dr. Garrett has nothing to disclose Outline PrEP Efficacy Adherence among populations Pharmacokinetic and pharmacodynamics relationship
More informationPrEP: Pre Exposure Prophylaxis
PrEP: Pre Exposure Prophylaxis Lyn Stevens, NP, MS, ACRN Deputy Director Office of the Medical Director NYS Department of Health, AIDS Institute Faculty Disclosure Lyn Stevens No relationships to disclose
More informationHIV: Pregnancy in Serodiscordant Couple. Dr Chow TS ID Clinic HPP
HIV: Pregnancy in Serodiscordant Couple Dr Chow TS ID Clinic HPP Sexual Reproductive Health and Rights The recognition of the sexual and reproductive health and rights (SRHR) of all individuals and couples
More informationDisclosure. Learning Objectives. Epidemiology. Transmission. Risk of Transmission PRE-EXPOSURE PROPHYLAXIS (PREP) FOR HIV PREVENTION 50,000.
Disclosure PRE-EXPOSURE PROPHYLAXIS (PREP) FOR HIV PREVENTION I have no financial interest in and/or affiliation with any external organizations in relation to this CE program. DaleMarie Vaughan, PharmD
More information11/8/2016. Moving Beyond Truvada: The (Current) Future Pipeline for PrEP. Prevention Modalities
Moving Beyond Truvada: The (Current) Future Pipeline for PrEP Raphael J. Landovitz, MD MSc Associate Professor of Medicine UCLA Center for Clinical AIDS Research & Education November 18, 2016 2 Million
More informationThe Big Picture: The current and evolving HIV prevention landscape
The Big Picture: The current and evolving HIV prevention landscape Patrick Ndase, MBChB, M.P.H University of Washington Beyond Phase III: Seeking stakeholder perspectives on next steps with the for HIV
More informationThe Big Picture: The current and evolving HIV prevention landscape
The Big Picture: The current and evolving HIV prevention landscape Sharon Hillier, Ph.D. University of Pittsburgh Beyond Phase III: Seeking civil society perspectives on next steps with the dapivirine
More informationUpdate on Biomedical Prevention. Thomas C. Quinn, MD, MSc
Update on Biomedical Prevention Thomas C. Quinn, MD, MSc Associate Director of International Research National Institute of Allergy and Infectious Diseases Director, Johns Hopkins Center for Global Health
More informationGetting Prepped for PrEP. Ken Ho, MD, MPH World AIDS Day
Getting Prepped for PrEP Ken Ho, MD, MPH World AIDS Day Objectives HIV epidemiology What is PrEP? Does it Work? Who gets PrEP? How do I prescribe PrEP What to do at the first visit? What to do at follow
More informationPre-Exposure Prophylaxis (PrEP) and the Governor s Plan to End AIDS: What Every Clinician Needs to Know
Pre-Exposure Prophylaxis (PrEP) and the Governor s Plan to End AIDS: What Every Clinician Needs to Know ANTONIO E. URBINA, MD Medical Director Associate Professor of Medicine Mt. Sinai Hospital Disclosure
More informationEvolving HIV Treatment Paradigms What we need to know
Evolving HIV Treatment Paradigms What we need to know Benjamin Young International Association of Providers of AIDS Care Washington, DC, USA Evolving HIV Treatment Paradigms When/who to treat Better medicines
More informationHIV Treatment Evolution. Kimberly Y. Smith MD MPH Vice President and Head, Global Research and Medical Strategy Viiv Healthcare
HIV Treatment Evolution Kimberly Y. Smith MD MPH Vice President and Head, Global Research and Medical Strategy Viiv Healthcare Overview of the Evolution of Antiretroviral Therapy Early Treatment 1987
More informationMoving beyond condoms to prevent HIV transmission. Are you Prepared for HIV PrEP?
Moving beyond condoms to prevent HIV transmission Are you Prepared for HIV PrEP? The Issues New HIV infections in the US continue Vast majority of infections are sexually acquired Condoms work but are
More informationCombination HIV Prevention
Combination HIV Prevention Timothy Mastro, MD, FACP, DTM&H FHI 360, Durham, North Carolina, USA 7 th INTEREST Workshop, Dakar, Senegal 15 May 2013 Outline What Works for HIV Prevention? Highly Active
More informationStrategic use of antiretroviral drugs to prevent HIV transmission
Strategic use of antiretroviral drugs to prevent HIV transmission 22th Tunisian Congress of Infectious Diseases 2nd Congress of Federation of Arab Societies of Clinical Microbiology and Infectious Diseases
More informationAntiretrovirals for HIV prevention:
Antiretrovirals for HIV prevention: Topical PrEP, Systemic PrEP and Treatment for Prevention Presentation at 6th International workshop on HIV treatment, pathogenesis and prevention research in resource-limited
More informationMTN-020. Jared Baeten, MD PhD Thesla Palanee, PhD On behalf of the ASPIRE team MTN Annual Meeting, Bethesda 21 February 2012
MTN-020 Jared Baeten, MD PhD Thesla Palanee, PhD On behalf of the ASPIRE team MTN Annual Meeting, Bethesda 21 February 2012 MTN-020 / ASPIRE A Multi-Center, Randomized, Double- Blind, Placebo-Controlled
More informationHIV Pre-Exposure Prophylaxis (PrEP)
HIV Pre-Exposure Prophylaxis (PrEP) Disclosures No disclosures to report Carlos Malvestutto, MD, MPH Assistant Professor, Internal Medicine Division of Infectious Diseases The Ohio State University College
More informationPre-exposure Prophylaxis. Robert M Grant October 2014
Pre-exposure Prophylaxis Robert M Grant October 2014 The HIV Pandemic 2.3 Million New HIV Infections in 2012 39% in Young People (ages 15-24) The HIV Pandemic 1.6 Million Started Therapy in 2012 1.4 New
More informationWOMEN & HIV: A GLOBAL UPDATE. Deanna Kerrigan, PhD, MPH Associate Professor Health, Behavior & Society
WOMEN & HIV: A GLOBAL UPDATE Deanna Kerrigan, PhD, MPH Associate Professor Health, Behavior & Society Objectives Review the current global burden of HIV among women Trends and progress to date Groups with
More informationAdolescent PrEP Delivery: Strategies and Tools to Maximize Adherence Young Women in Africa. Jessica Haberer, MD, MS November 9, 2017
Adolescent PrEP Delivery: Strategies and Tools to Maximize Adherence Young Women in Africa Jessica Haberer, MD, MS November 9, 2017 Disclosures I have no conflicts to declare Grant funding: NIH, Gates
More informationThe role of Integrase Inhibitors during HIV prevention
The role of Integrase Inhibitors during HIV prevention Pep Coll AIDS Research Institute-IrsiCaixa Fight AIDS Foundation BCN Checkpoint 2nd Global HIV Clinical Forum: Integrase Inhibitors Paris July 22th
More informationPEP and PrEP: AWAAC 2014
Acknowledgements: HIVCS PEP guidelines group, Helen Rees, Slim Abdool Karim, Quarraisha Abdool Karim, Clinical Care Options, Edwina Wright, Jared Baeton, AETC PEP and PrEP: AWAAC 2014 Francois Venter Wits
More informationInspiring HIV Prevention Innovations for Women. IPM Satellite Event Durban, 13 th June 2017 Annalene Nel
Inspiring HIV Prevention Innovations for Women IPM Satellite Event Durban, 13 th June 2017 Annalene Nel HIV Infection: Where We Are Today 30+ years since the US CDC reported the first cases of AIDS 25.5
More informationUK community perspective on PrEP and PROUD. Simon Collins
UK community perspective on PrEP and PROUD Simon Collins Overview Community perspective on PrEP: 3 myths and 5 community issues (Glasgow) The PROUD study and UK experience Update from CROI - February 2015
More informationPre-Exposure Topical Microbicides and Oral Prophylaxis Trials:
Pre-Exposure Topical Microbicides and Oral Prophylaxis Trials: Rationale, Designs & Issues Connie Celum, MD, MPH Patrick Ndase, MBChB, MPH May 2007 Regional MTN Meeting Importance of HIV prevention Antiretroviral
More informationPre-Exposure Prophylaxis (PrEP) A Biomedical Intervention Prevention with Negatives Antiretroviral Prevention
Pre-Exposure Prophylaxis (PrEP) A Biomedical Intervention Prevention with Negatives Antiretroviral Prevention New and Emerging Biomedical HIV Prevention Interventions Vaccines Vaginal microbicides Pre-exposure
More informationQUESTIONS AND ANSWERS ABOUT PARTNERS PrEP AND VOICE
CONTACT: Lisa Rossi +1-412-641-8940 +1-412- 916-3315 (mobile) rossil@upmc.edu QUESTIONS AND ANSWERS ABOUT PARTNERS PrEP AND VOICE 1. What is the Partners PrEP study? The Partners PrEP Study is a double-blind,
More informationHIV Pre-Exposure Prophylaxis (PrEP)
HIV Pre-Exposure Prophylaxis (PrEP) Carlos Malvestutto, MD, MPH Assistant Professor, Internal Medicine Division of Infectious Diseases The Ohio State University College of Medicine Disclosures No disclosures
More informationOR: Steps you can take in the clinic to prevent HIV infections
Implementing Changes to Reduce HIV Incidence: Synergies between Public Health and Primary Care Kevin Ard, MD, MPH Brigham and Women s Hospital, Massachusetts General Hospital, and the Fenway Institute
More informationWhere We Have Been and Where We are Going. Ian McGowan MD PhD FRCP
Where We Have Been and Where We are Going Ian McGowan MD PhD FRCP Directions Where we were Where we are headed Where we are 2005 The size of your dreams must always exceed your current capacity to achieve
More informationPRE-EXPOSURE PROPHYLAXIS FOR HIV: EVIDENCE AND GENDER CONSIDERATIONS. Jean R. Anderson M.D. Director, Johns Hopkins HIV Women s Health Program
PRE-EXPOSURE PROPHYLAXIS FOR HIV: EVIDENCE AND GENDER CONSIDERATIONS Jean R. Anderson M.D. Director, Johns Hopkins HIV Women s Health Program Disclosures None Objectives Review the evidence regarding the
More informationWelcome to the National Association of County and City Health Officials Webinar on PrEP and Local Health Departments
Welcome to the National Association of County and City Health Officials Webinar on PrEP and Local Health Departments There are two options for accessing the audio portion of this webinar: (1) Using your
More informationDominic Chow, MD, PhD, MPH, Hawaii Center for AIDS Kunane Dreier, Prevention, Life Foundation Kekoa Kealoha, Hawaii Island HIV/AIDS Foundation Alexis
Dominic Chow, MD, PhD, MPH, Hawaii Center for AIDS Kunane Dreier, Prevention, Life Foundation Kekoa Kealoha, Hawaii Island HIV/AIDS Foundation Alexis Charpentier, Harm Reduction Services Branch, Hawaii
More informationPrEP adherence in Black MSM in HPTN 073 and Beyond
PrEP adherence in Black MSM in HPTN 073 and Beyond Steven Shoptaw PhD { University of California Los Angeles June 24, 2014 With updates on HPTN 069 and HPTN 077 Overview Brief Epi PrEP rationale HPTN 073
More informationIntegrating PrEP with Early Antiretroviral Initiation Kenneth H. Mayer, MD
Integrating PrEP with Early Antiretroviral Initiation Kenneth H. Mayer, MD 2018 Controlling the HIV Epidemic Summit, Geneva May 3 rd, 2018 thefenwayinstitute.org The Key Paradigm: Test and Treat (when
More informationOn the Horizon for Consideration: Biomedical Advances in HIV Prevention
On the Horizon for Consideration: Biomedical Advances in HIV Prevention Francisco Ruiz, MS Senior Manager, National Alliance of State and Territorial AIDS Directors New Jersey Governor's Advisory Council
More informationRecent Breakthroughs in HIV Prevention for Men who Have Sex with Men and Transgender Populations
Recent Breakthroughs in HIV Prevention for Men who Have Sex with Men and Transgender Populations Kevin Ard, MD, MPH Brigham and Women s Hospital The Fenway Institute Boston, MA Funding: The New England
More informationPrEP in young African women: Rationale & lessons from HPTN 082
PrEP in young African women: Rationale & lessons from HPTN 082 Connie Celum MD MPH Departments of Global Health and Medicine University of Washington Disproportionate Success in HIV Epidemic Control by
More informationTranslating the Science to End New HIV Infections in Kenya
Translating the Science to End New HIV Infections in Kenya Perspectives, Practices and Lessons Nairobi, 28-30 May 2017 www.iasociety.org AIDS 2016 Post-Conference Workshop Setting the Stage Overview of
More informationUpdate on Antiretroviral-Based HIV Prevention
Update on Antiretroviral-Based HIV Prevention Prof. Janneke van de Wijgert University of Liverpool, Institute of Infection and Global Health Click to edit Master subtitle style 12th European Meeting on
More informationZero HIV infections Zero HIV deaths Zero HIV stigma. Stephanie Cohen, MD, MPH on behalf of the Getting to Zero Consortium
Zero HIV infections Zero HIV deaths Zero HIV stigma Stephanie Cohen, MD, MPH on behalf of the Getting to Zero Consortium Number of New HIV Diagnoses Overall decline in new HIV diagnoses and death in San
More informationThe Evidence Base for Women
The Evidence Base for Women Dr. Busisiwe Msimanga-Radebe WHO South Africa country office ICASA 2017 Abidjan, Cote d Ivoire Combination prevention to break the cycle of HIV transmission Men
More informationWhat s in the Biomedical Prevention Pipeline
What s in the Biomedical Prevention Pipeline HIV Endgame: Closing Gaps in the Care Cascade Toronto, 24 th October 2016 Ian McGowan MD DPhil FRCP University of Pittsburgh Pittsburgh, PA, USA Presenter Disclosure
More informationIAPAC Summit Daily And Intermittent PrEP
IAPAC Summit 2012 Daily And Intermittent PrEP Six Clinical Trial Sites Nyanga District Population: 500 000 Unemployment: 70% Shack dwelling 50% Background The Global iprex Study Design Double blind,
More informationART FOR HIV PREVENTION: PANACEA OR PANDORA S BOX? KENNETH H. MAYER, M.D.
ART FOR HIV PREVENTION: PANACEA OR PANDORA S BOX? KENNETH H. MAYER, M.D. HIV TRANSMISSION SIGNIFICANT, LOW PROBABILITY EVENT (
More informationARVs for prevention in at-risk populations: Microbicides
ARVs for prevention in at-risk populations: Microbicides Treatment as Prevention in Africa Meeting Botswana, April 30 May 3, 2014 Salim S Abdool Karim Director: CAPRISA Pro Vice-Chancellor (Research):
More informationPrEP for Women: HIV Prevention in Family Planning Settings
National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention PrEP for Women: HIV Prevention in Family Planning Settings Dawn K. Smith, MD, MS, MPH Division of HIV/AIDS Prevention dsmith1@cdc.gov
More informationPre exposure Prophylaxis (PrEP): Stepping Up HIV Prevention
Pre exposure Prophylaxis (PrEP): Stepping Up HIV Prevention Dawn K. Smith, MD, MS, MPH Centers for Disease Control and Prevention The findings and conclusions in this presentation have not been formally
More informationPre-Sexual Exposure Prophylaxis (PrEP)
Projeto Praça Onze Universidade Federal do Rio de Janeiro Pre-Sexual Exposure Prophylaxis (PrEP) Mauro Schechter Principal Investigator, Projeto Praça Onze Professor of Infectious Diseases Universidade
More informationHIV Prevention among Women
HIV Prevention among Women Assistant Professor of Medicine Division of Infectious Diseases Baylor College of Medicine Disclosures: Gilead Sciences - Scientific Advisory Board; Investigatorinitiated research
More informationETHICS IN HIV PREVENTION RESEARCH IN THE NEW ERA OF
ETHICS IN HIV PREVENTION RESEARCH IN THE NEW ERA OF PrEP MTN Regional Meeting Cape Town 20 September 2017 Dhevium Govender South African Medical Research Council HIV Prevention Research Unit Quality/Regulatory
More informationPrEP Guidelines for the Ob/Gyn. Outline. 1. How many patient have you discussed PrEP with this year?
PrEP Guidelines for the Ob/Gyn Megan J. Huchko, MD, MPH Obstetrics and Gynecology Update October 14, 2015 I have no financial or other conflicts of interest to declare Outline The Need for PrEP: HIV Treatment
More informationPrEP efficacy the evidence
PrEP efficacy the evidence Dr Michael Brady Consultant, HIV and Sexual Health King s College Hospital, London Medical Director Terrence Higgins Trust PrEP Pre-exposure prophylaxis Tenofovir and emtricitabine
More informationChristina Psaros, Ph.D. (presenting author) Massachusetts General Hospital / Harvard Medical School, Boston, MA
Evaluation and process outcomes from an adherence intervention to support HIV pre-exposure prophylaxis (PrEP) adherence in HIV serodiscordant couples in Uganda Christina Psaros, Ph.D. (presenting author)
More informationThe HIV Prevention Product Pipeline for Adolescents JANUARY 8 TH, 2018
The HIV Prevention Product Pipeline for Adolescents SYBIL HOSEK, PHD DEPARTMENT OF PSYCHIATRY, STROGER HOSPITAL OF COOK COUNTY I NTER-CFAR ARV FOR PREVENTION WORKING GROUP WEBINAR JANUARY 8 TH, 2018 Conflicts
More informationTasP - Individual versus Public Health Benefit versus Both.
Site Map l Contact Us l Calendar l Join AVAC Donate TasP - Individual versus Public Health Benefit versus Both. Kevin Fisher Policy Director, AVAC June 2012 Multiple choice answer: all of the above We
More informationHIV Prevention. Recent Advances and Implications for the Caribbean
HIV Prevention Recent Advances and Implications for the Caribbean Chris Behrens, MD CCAS/CHART Conference Barbados, August 2010 Cases 200 180 160 140 120 100 80 60 40 20 0 Year HIV Cases AIDS Cases HIV
More informationPre-Exposure Prophylaxis for HIV Prevention
Pre-Exposure Prophylaxis for HIV Prevention Raphael J. Landovitz, MD MSc Associate Professor of Medicine UCLA Center for Clinical AIDS Research & Education April 15, 2016 2 Million New Infections in 2014
More informationPre-Exposure Prophylaxis (PrEP) 1 Prevention of HIV in At-Risk Women:
Pre-Exposure Prophylaxis (PrEP) 1 Prevention of HIV in At-Risk Women: Coming of Age Aaron Kofman, BA, MD 14 Eli Y. Adashi, MD, MS, CPE, FACOG BRIGHT Series June 12, 2012 Women and the HIV Epidemic Global
More informationPharmacology Lessons from Chemoprophylaxis Studies. Marta Boffito, MD, PhD St Stephen s AIDS Trust Chelsea and Westminister Hospital London, UK
Pharmacology Lessons from Chemoprophylaxis Studies Marta Boffito, MD, PhD St Stephen s AIDS Trust Chelsea and Westminister Hospital London, UK Pre tenofovir generation 1996-2009 PK did not inform trials
More informationDr Valérie Martinez-Pourcher
Educa&ng Nurses About An&retrovirals and HIV Preven&on - State of the Science, Uptake Challenges, and Barriers Dr Valérie Martinez-Pourcher Pitié-Salpêtrière Hospital Paris We need to control HIV replication
More informationMTN-001 Phase 2 Adherence and Pharmacokinetic Study of Oral and Vaginal Preparations of Tenofovir
MTN-001 Phase 2 Adherence and Pharmacokinetic Study of Oral and Vaginal Preparations of Tenofovir Craig Hendrix, Alexandra Minnis, Vijayanand Guddera, Sharon Riddler, Robert Salata, Clemensia Nakabiito,
More informationTaking a shot at HIV with longacting injectable ARVs for treatment and prevention
Taking a shot at HIV with longacting injectable ARVs for treatment and prevention Martin Markowitz M.D. Clinical Director and Staff Investigator Aaron Diamond AIDS Research Center Aaron Diamond Professor
More informationCan we treat our way out of the HIV epidemic?
Can we treat our way out of the HIV epidemic? Richard E. Chaisson, MD Center for AIDS Research Center for TB Research Johns Hopkins University Schoolboy s (and politician s) tricks for evading the question
More informationPEP and PREP. Dr David Hawkins Chelsea and Westminster Hospital
PEP and PREP Dr David Hawkins Chelsea and Westminster Hospital Opportunities for biomedical interventions YEARS HOURS 72 HOURS YEARS Prior to exposure Exposure (pre-coital/ coital) Exposure (pre-coital/
More informationProfessor Thomas Quinn Johns Hopkins Center for Global Health, Maryland, USA
17 TH ANNUAL CONFERENCE OF THE BRITISH HIV ASSOCIATION (BHIVA) Professor Thomas Quinn Johns Hopkins Center for Global Health, Maryland, USA 6-8 April 2011, Bournemouth International Centre 17 TH ANNUAL
More informationHow Do You Like Your PrEP?
How Do You Like Your PrEP? Results from the HPTN 067/ADAPT Study Presented by Robert Grant, MD, MPH on behalf of the HPTN 067/ADAPT Study Team Background Oral FTC/TDF PrEP is effective for preventing HIV
More information